K F Adams

Summary

Affiliation: University of North Carolina
Country: USA

Publications

  1. ncbi request reprint Patients with mild heart failure worsen during withdrawal from digoxin therapy
    K F Adams
    Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, USA
    J Am Coll Cardiol 30:42-8. 1997
  2. ncbi request reprint Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure
    Kirkwood F Adams
    Division of Cardiology, Heart Failure Program, School of Medicine, University of North Carolina, 6110 Falconbridge Road, Suite 101, Chapel Hill, NC 27517, USA
    Am J Health Syst Pharm 61:S4-13. 2004
  3. ncbi request reprint B-type natriuretic peptide: from bench to bedside
    Kirkwood F Adams
    Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7075, USA
    Am Heart J 145:S34-46. 2003
  4. doi request reprint Systems biology and heart failure: concepts, methods, and potential research applications
    Kirkwood F Adams
    UNC Heart Failure Program, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
    Heart Fail Rev 15:371-98. 2010
  5. doi request reprint Biomarker guided therapy for heart failure: focus on natriuretic peptides
    Kirkwood F Adams
    Department of Medicine, School of Medicine, UNC Heart Failure Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
    Heart Fail Rev 15:351-70. 2010
  6. doi request reprint Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry
    Kirkwood F Adams
    Department of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA
    Am Heart J 157:926-32. 2009
  7. ncbi request reprint Clinical predictors of in-hospital mortality in acutely decompensated heart failure-piecing together the outcome puzzle
    Kirkwood F Adams
    Department of Medicine, School of Medicine, University of North Carolina Heart Failure Program, Chapel Hill, NC 27514, USA
    Congest Heart Fail 14:127-34. 2008
  8. doi request reprint Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure
    Kirkwood F Adams
    Department of Medicine and Radiology, University of North Carolina Chapel Hill, Chapel Hill, NC 27514, USA
    Am Heart J 160:1142-8. 2010
  9. ncbi request reprint How should COMET influence heart failure practice?
    Kirkwood F Adams
    The University of North Carolina at Chapel Hill Heart Failure Program, 6110 Falconbridge Road, Suite 101, Chapel Hill, NC 27517, USA
    Curr Heart Fail Rep 1:67-71. 2004
  10. ncbi request reprint Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
    Kirkwood F Adams
    Division of Cardiology, University of North Carolina, Chapel Hill, NC, USA
    Am Heart J 149:209-16. 2005

Detail Information

Publications71

  1. ncbi request reprint Patients with mild heart failure worsen during withdrawal from digoxin therapy
    K F Adams
    Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, USA
    J Am Coll Cardiol 30:42-8. 1997
    ..We investigated whether patients with mild heart failure due to left ventricular systolic dysfunction were at risk of worsening during digoxin withdrawal...
  2. ncbi request reprint Pathophysiologic role of the renin-angiotensin-aldosterone and sympathetic nervous systems in heart failure
    Kirkwood F Adams
    Division of Cardiology, Heart Failure Program, School of Medicine, University of North Carolina, 6110 Falconbridge Road, Suite 101, Chapel Hill, NC 27517, USA
    Am J Health Syst Pharm 61:S4-13. 2004
    ..The pathophysiology of heart failure is reviewed, with particular focus on the role of abnormal neurohormonal activation of the sympathetic nervous system and the renin-angiotensin-aldosterone axis in the pathophysiology of this syndrome...
  3. ncbi request reprint B-type natriuretic peptide: from bench to bedside
    Kirkwood F Adams
    Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599 7075, USA
    Am Heart J 145:S34-46. 2003
  4. doi request reprint Systems biology and heart failure: concepts, methods, and potential research applications
    Kirkwood F Adams
    UNC Heart Failure Program, Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
    Heart Fail Rev 15:371-98. 2010
    ....
  5. doi request reprint Biomarker guided therapy for heart failure: focus on natriuretic peptides
    Kirkwood F Adams
    Department of Medicine, School of Medicine, UNC Heart Failure Program, University of North Carolina at Chapel Hill, Chapel Hill, NC 27514, USA
    Heart Fail Rev 15:351-70. 2010
    ..Although pilot work has provided encouraging results, appropriately designed, large-scale, prospective randomized trials are needed to confirm these preliminary findings and definitively establish this therapeutic approach...
  6. doi request reprint Prospective assessment of the occurrence of anemia in patients with heart failure: results from the Study of Anemia in a Heart Failure Population (STAMINA-HFP) Registry
    Kirkwood F Adams
    Department of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, NC 27514, USA
    Am Heart J 157:926-32. 2009
    ..Although a potentially important pathophysiologic factor in heart failure, the prevalence and predictors of anemia have not been well studied in unselected patients with heart failure...
  7. ncbi request reprint Clinical predictors of in-hospital mortality in acutely decompensated heart failure-piecing together the outcome puzzle
    Kirkwood F Adams
    Department of Medicine, School of Medicine, University of North Carolina Heart Failure Program, Chapel Hill, NC 27514, USA
    Congest Heart Fail 14:127-34. 2008
    ..1% to 21.9%. Although risk stratification alone cannot improve outcomes, identification of patients at high and low risk may improve resource utilization and better focus the intensity of care according to outcome...
  8. doi request reprint Prospective evaluation of the association between cardiac troponin T and markers of disturbed erythropoiesis in patients with heart failure
    Kirkwood F Adams
    Department of Medicine and Radiology, University of North Carolina Chapel Hill, Chapel Hill, NC 27514, USA
    Am Heart J 160:1142-8. 2010
    ..We prospectively evaluated the relationship between this marker and hematopoietic disturbances in heart failure...
  9. ncbi request reprint How should COMET influence heart failure practice?
    Kirkwood F Adams
    The University of North Carolina at Chapel Hill Heart Failure Program, 6110 Falconbridge Road, Suite 101, Chapel Hill, NC 27517, USA
    Curr Heart Fail Rep 1:67-71. 2004
    ..Further studies are needed to determine whether there are additional clinical benefits from the inhibition of adrenergic receptors beyond the proven benefits of b1-blockade...
  10. ncbi request reprint Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE)
    Kirkwood F Adams
    Division of Cardiology, University of North Carolina, Chapel Hill, NC, USA
    Am Heart J 149:209-16. 2005
    ..Most available data on these patients are limited by patient selection criteria and study design of clinical trials and single-center studies...
  11. ncbi request reprint Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis investigation group trial: a retrospective analysis
    Kirkwood F Adams
    Department of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27517, USA
    J Am Coll Cardiol 46:497-504. 2005
    ..The purpose of this study was to investigate the relationship of serum digoxin concentration (SDC) and outcomes in women with heart failure (HF)...
  12. ncbi request reprint Are angiotensin-converting enzyme inhibitors and beta-blockers making an impact on the epidemiology of heart failure?
    Kirkwood F Adams
    University of North Carolina Heart Failure Program, 6110 Falconbridge Road, Suite 101, Chapel Hill, NC 27517, USA
    Curr Cardiol Rep 6:162-8. 2004
    ..These agents are capable of substantially reducing the morbidity and mortality associated with heart failure. However, the importance of enhanced physician and public awareness of heart failure remains critical in the future...
  13. doi request reprint Beta-blockers in heart failure: how far have we progressed?
    Kirkwood F Adams
    University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC 27599 7075, USA
    Postgrad Med 112:7-15. 2002
    ..Mechanistic and early clinical trials are reviewed, along with the results from CIBIS-II, MERIT-HF, and COPERNICUS. Barriers to the use of beta-blocker therapy also are discussed...
  14. doi request reprint Prospective evaluation of the association between hemoglobin concentration and quality of life in patients with heart failure
    Kirkwood F Adams
    Department of Medicine and Radiology, University of North Carolina Chapel Hill, Chapel Hill, NC 27514, USA
    Am Heart J 158:965-71. 2009
    ..Reduced hemoglobin has been associated with adverse outcomes in heart failure, but the relationship of hemoglobin to health-related quality of life in outpatients with this syndrome has not been well studied...
  15. ncbi request reprint Clinical predictors of worsening heart failure during withdrawal from digoxin therapy
    K F Adams
    Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill, 27599 7075, USA
    Am Heart J 135:389-97. 1998
    ....
  16. ncbi request reprint Clinical benefits of low serum digoxin concentrations in heart failure
    Kirkwood F Adams
    Departments of Medicine and Radiology, School of Medicine, University of North Carolina, Chapel Hill, North Carolina 27599 7075, USA
    J Am Coll Cardiol 39:946-53. 2002
    ..We sought to determine whether there was a relationship between serum digoxin concentration (SDC), including SDCs typically regarded as low, and clinical efficacy related to digoxin in patients with symptomatic left ventricular dysfunction...
  17. ncbi request reprint Angiotensin-converting enzyme inhibition and vascular remodeling in coronary artery disease
    K F Adams
    Department of Medicine, School of Medicine, University of North Carolina at Chapel Hill 27599 7075, USA
    Coron Artery Dis 9:675-84. 1998
    ....
  18. ncbi request reprint Gender differences in survival in advanced heart failure. Insights from the FIRST study
    K F Adams
    University of North Carolina at Chapel Hill, 27599 7075, USA
    Circulation 99:1816-21. 1999
    ..This study investigates whether a similar survival advantage for women would be evident among patients with advanced heart failure...
  19. ncbi request reprint Translating heart failure guidelines into clinical practice: clinical science and the art of medicine
    K F Adams
    Division of Cardiology, University of North Carolina at Chapel Hill, CB 7075, Burnett Womack Building, Chapel Hill, NC 27599, USA
    Curr Cardiol Rep 3:130-5. 2001
    ..The recent guideline process for a specific chronic cardiovascular disease, heart failure, is used for illustration of the translation process...
  20. ncbi request reprint Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. MOCHA Investigators
    M R Bristow
    Division of Cardiology, University of Colorado HSC, Denver 80262, USA
    Circulation 94:2807-16. 1996
    ..We conducted a multicenter, placebo-controlled trial designed to establish the efficacy and safety of carvedilol, a "third-generation" beta -blocking agent with vasodilator properties, in chronic heart failure...
  21. ncbi request reprint Clinical outcomes in patients on beta-blocker therapy admitted with worsening chronic heart failure
    Wendy A Gattis
    Duke University Medical Center Duke Clinical Research Institute, Division of Cardiology, Durham, North Carolina 27705, USA
    Am J Cardiol 91:169-74. 2003
    ..These results also suggest that caution should be taken when withdrawing beta blockade in this population...
  22. ncbi request reprint Selective versus nonselective beta-blockade for heart failure therapy: are there lessons to be learned from the COMET trial?
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, Denver, Colorado 80262, USA
    J Card Fail 9:444-53. 2003
    ....
  23. doi request reprint Validation and potential mechanisms of red cell distribution width as a prognostic marker in heart failure
    Larry A Allen
    Division of Cardiology, University of Colorado Denver, Aurora, CO, USA
    J Card Fail 16:230-8. 2010
    ..Our study sought to validate the prognostic value of RDW in heart failure and to explore the potential mechanisms underlying this association...
  24. ncbi request reprint Rationale and design of the pilot randomized study of nesiritide versus dobutamine in heart failure (PRESERVD-HF)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S55-7. 2003
  25. ncbi request reprint Effect of fluoxetine on carvedilol pharmacokinetics, CYP2D6 activity, and autonomic balance in heart failure patients
    D W Graff
    Division of Pharmacotherapy, University of North Carolina School of Pharmacy, Chapel Hill, NC 27599-7360, USA
    J Clin Pharmacol 41:97-106. 2001
    ..However, this interaction was of little clinical significance in our sample population...
  26. ncbi request reprint New epidemiologic perspectives concerning mild-to-moderate heart failure
    K F Adams
    Departments of Medicine and Radiology, School of Medicine, University of North Carolina at Chapel Hill, 27599-7075, USA
    Am J Med 110:6S-13S. 2001
    ..These data highlight the importance of enhancing physician and public awareness of heart failure. New methods of molecular epidemiology will point toward better and earlier detection of this common and frequently fatal condition...
  27. ncbi request reprint The Pilot Randomized Study of Nesiritide Versus Dobutamine in Heart Failure (PRESERVD-HF)
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA
    Am J Cardiol 96:18G-25G. 2005
    ..Accordingly, therapies for AHFS that are aimed at improving hemodynamics may affect long-term prognosis by either injuring or salvaging myocardium...
  28. ncbi request reprint Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial
    Michael S Cuffe
    Northwestern University Medical School, Division of Cardiology, 201 E Huron St, Galter 10 240, Chicago, IL 60611, USA
    JAMA 287:1541-7. 2002
    ..Although intravenous inotropic therapy usually produces beneficial hemodynamic effects and is labeled for use in the care of such patients, the effect of such therapy on intermediate-term clinical outcomes is uncertain...
  29. pmc Independent prognostic value of echocardiography and N-terminal pro-B-type natriuretic peptide in patients with heart failure
    Alan L Hinderliter
    Division of Cardiology, University of North Carolina, Chapel Hill, NC 27559 7075, USA
    Am Heart J 156:1191-5. 2008
    ..Whether cardiac ultrasound and natriuretic peptides provide independent prognostic information is uncertain...
  30. ncbi request reprint The COMET trial
    Michael R Bristow
    Division of Cardiology, University of Colorado Health Sciences Center, B130, Room 6430, 4200 East Ninth Avenue, Denver, CO 80262, USA
    Congest Heart Fail 11:39-47. 2005
  31. ncbi request reprint Relationship of depression to death or hospitalization in patients with heart failure
    Andrew Sherwood
    Department of Psychiatry, Duke University Medical Center, Durham, NC, USA
    Arch Intern Med 167:367-73. 2007
    ..However, patients with heart failure (HF) have been less frequently studied, and the effect of depression on prognosis, independent of disease severity, is uncertain...
  32. ncbi request reprint Survival rates are similar between African American and white patients with heart failure
    Stephanie H Dunlap
    Department of Medicine, School of Medicine, University of Illinois at Chicago, Chicago, Ill, USA
    Am Heart J 146:265-72. 2003
    ..We investigated the hypothesis that race also influences the survival of patients with heart failure...
  33. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the Randomized Intravenous Tezosentan study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, University of North Carolina, Chapel Hill, NC 27705, USA
    Am Heart J 144:583-8. 2002
    ..Tezosentan is a dual endothelin receptor antagonist, and it has improved cardiac output and reduced pulmonary and systemic vascular resistance in experimental animal models and in initial human acute decompensated heart failure studies...
  34. ncbi request reprint Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    JAMA 291:1963-71. 2004
    ..In contrast to diuretics, the vasopressin antagonist tolvaptan may increase net volume loss in heart failure without adversely affecting electrolytes and renal function...
  35. ncbi request reprint Surrogate end points in heart failure
    Craig R Lee
    School of Pharmacy, Division of Pharmacotherapy, University of North Carolina at Chapel Hill, 27599 7360, USA
    Ann Pharmacother 36:479-88. 2002
    ....
  36. ncbi request reprint Rationale and study design for a multicenter, randomized, double-blind, placebo-controlled study of the effects of tolvaptan on the acute and chronic outcomes of patients hospitalized with worsening congestive heart failure
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S51-4. 2003
  37. ncbi request reprint Digoxin in the management of cardiovascular disorders
    Mihai Gheorghiade
    Division of Cardiology, Northwestern University Feinberg School of Medicine, Galter 10 240, 201 East Huron St, Chicago, Ill 60611 2908, USA
    Circulation 109:2959-64. 2004
  38. doi request reprint Early worsening heart failure in patients admitted with acute heart failure--a new outcome measure associated with long-term prognosis?
    Beth Davison Weatherley
    Momentum Research Inc, Durham, NC, USA
    Fundam Clin Pharmacol 23:633-9. 2009
    ..7-6.3). Early WHF is a common adverse event in patients admitted with AHF, and is associated with AHF severity and excessive 6-month mortality. WHF should be considered as a clinically important endpoint in AHF studies...
  39. ncbi request reprint Vasopressin: a new target for the treatment of heart failure
    Craig R Lee
    School of Pharmacy, University of North Carolina at Chapel Hill, 27599 7075, USA
    Am Heart J 146:9-18. 2003
    ..Arginine vasopressin is a peptide hormone that modulates a number of processes implicated in the pathogenesis of heart failure. Numerous vasopressin antagonists are currently under development for the treatment of this syndrome...
  40. ncbi request reprint Synergistic polymorphisms of beta1 and alpha2C-adrenergic receptors and the influence on left ventricular ejection fraction response to beta-blocker therapy in heart failure
    Maximilian T Lobmeyer
    Department of Pharmacy Practice, University of Florida, Gainesville, FL 32610, USA
    Pharmacogenet Genomics 17:277-82. 2007
    ..We tested whether the ADRA2C insertion/deletion polymorphism was associated with beta-blocker response in heart failure, either alone or in combination with the ADRB1Arg389Gly polymorphism...
  41. ncbi request reprint Surrogate end points in heart failure trials
    Mihai Gheorghiade
    Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S67-70. 2003
  42. ncbi request reprint Metoprolol reverses left ventricular remodeling in patients with asymptomatic systolic dysfunction: the REversal of VEntricular Remodeling with Toprol-XL (REVERT) trial
    Wilson S Colucci
    Cardiovascular Medicine, Boston University Medical Center, 88 E Newton St, Boston, MA 02118, USA
    Circulation 116:49-56. 2007
    ..We investigated whether beta-blocker therapy ameliorates left ventricular remodeling in asymptomatic patients with left ventricular systolic dysfunction...
  43. ncbi request reprint Acute heart failure syndromes: clinical scenarios and pathophysiologic targets for therapy
    Leonardo De Luca
    Department of Cardiovascular Sciences, Laboratory of Interventional Cardiology, European Hospital, Rome, Italy
    Heart Fail Rev 12:97-104. 2007
    ....
  44. ncbi request reprint Prognostic value of blood urea nitrogen in patients hospitalized with worsening heart failure: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) study
    Gerasimos Filippatos
    Department of Cardiology, Athens University, Athens, Greece
    J Card Fail 13:360-4. 2007
    ..The association between baseline blood urea nitrogen (BUN) and clinical outcomes in patients admitted for ADHF was evaluated in a post-hoc analysis of the ACTIV in CHF trial...
  45. ncbi request reprint Usefulness of an elevated troponin-I in predicting clinical events in patients admitted with acute heart failure and acute coronary syndrome (from the RITZ-4 trial)
    Wendy A Gattis
    Duke Clinical Research Institute, Duke University Medical Center, 2400 N Pratt Street, Box 17969, Durham, NC 27710, USA
    Am J Cardiol 93:1436-7, A10. 2004
    ..One hundred ninety-two patients were enrolled in this study. Patients with baseline cTnI values were included in this analysis, and the relation between cTnI and the composite clinical primary end point of RITZ-4 was evaluated...
  46. pmc Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial
    Vic Hasselblad
    Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 27705, USA
    Eur J Heart Fail 9:1064-9. 2007
    ..We examined the relation of maximal in-hospital diuretic dose to weight loss, changes in renal function, and mortality in hospitalised heart failure (HF) patients...
  47. ncbi request reprint The pathophysiology of acute heart failure--is it all about fluid accumulation?
    Gad Cotter
    Duke University Medical Center, The Duke Clinical Research Institute, Durham, NC 27715, USA
    Am Heart J 155:9-18. 2008
    ....
  48. ncbi request reprint Concomitant use of a positive inotropic agent to create a bridge to the successful initiation of beta-blocker therapy in patients with heart failure: a proposal for a trial
    Manuela Zampino
    Northwestern University, Feinberg School of Medicine, Chicago, Ill 60611, USA
    Am Heart J 145:S62-6. 2003
  49. ncbi request reprint The problem of decompensated heart failure: nomenclature, classification, and risk stratification
    G Michael Felker
    Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 145:S18-25. 2003
    ..It also defines the current understanding of strategies for risk stratification in the setting of decompensated heart failure...
  50. ncbi request reprint Dissociation between hemodynamic changes and symptom improvement in patients with advanced congestive heart failure
    Monica R Shah
    Duke Clinical Research Institute, P O Box 17969, Durham, NC 27715, USA
    Eur J Heart Fail 4:297-304. 2002
    ..Changes in hemodynamic measures often serve as surrogate end points in efficacy trials for advanced heart failure, although there are few objective data to support this practice...
  51. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 41:1452-7. 2003
    ..We sought to determine the effect of tezosentan in patients with acute decompensated heart failure (HF) associated with acute coronary syndrome (ACS)...
  52. pmc Hospitalizations due to unstable angina pectoris in diastolic and systolic heart failure
    Ali Ahmed
    University of Alabama at Birmingham, Alabama, USA
    Am J Cardiol 99:460-4. 2007
    ..As in patients with systolic HF, those with diastolic HF should be routinely evaluated for myocardial ischemia and managed accordingly...
  53. ncbi request reprint Risk stratification after hospitalization for decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, 2400 Pratt Street, Room 0311, Terrace Level, Durham, NC 27705, USA
    J Card Fail 10:460-6. 2004
    ..We used data from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) study to develop a model that would predict outcomes in patients with decompensated HF...
  54. ncbi request reprint Gender differences in advanced heart failure: insights from the BEST study
    Jalal K Ghali
    Cardiac Centers of Louisiana, Shreveport, Louisiana 71103, USA
    J Am Coll Cardiol 42:2128-34. 2003
    ..The goal of this study was to determine the influence of gender on baseline characteristics, response to treatment, and prognosis in patients with heart failure (HF) and impaired left ventricular ejection fraction (LVEF)...
  55. ncbi request reprint beta-Adrenergic receptor polymorphisms and responses during titration of metoprolol controlled release/extended release in heart failure
    Steven G Terra
    Department of Pharmacy Practice, University of Florida, Gainsville, FL 32610, USA
    Clin Pharmacol Ther 77:127-37. 2005
    ..We also tested whether polymorphisms in the beta(2)-adrenergic receptor, G-protein alpha s subunit (G(s)alpha), and cytochrome P450 (CYP) 2D6 genes or S-metoprolol plasma concentrations were associated with beta-blocker tolerability...
  56. ncbi request reprint Usefulness of anemia as a predictor of death and rehospitalization in patients with decompensated heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    Am J Cardiol 92:625-8. 2003
    ..Lower baseline hemoglobin is associated with risk of short-term adverse clinical outcomes in this population, even after controlling for other baseline differences...
  57. ncbi request reprint Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy
    Steven G Terra
    Department of Pharmacy Practice, University of Florida College of Pharmacy, Gainesville, FL 32610, USA
    Pharmacogenet Genomics 15:227-34. 2005
    ..We hypothesized that polymorphisms at codon 389 (Arg389Gly) and 49 (Ser49Gly) in the beta1-adrenergic receptor (AR) gene were associated with LV reverse remodeling changes in response to beta-blocker therapy among heart failure patients...
  58. ncbi request reprint Lower serum sodium is associated with increased short-term mortality in hospitalized patients with worsening heart failure: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF) s
    Liviu Klein
    Northwestern University Feinberg School of Medicine, Chicago, Ill 60611, USA
    Circulation 111:2454-60. 2005
    ..The prognostic value of serum sodium in patients hospitalized for worsening heart failure has not been well defined...
  59. ncbi request reprint In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE)
    William T Abraham
    Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio, USA
    J Am Coll Cardiol 46:57-64. 2005
    ..We sought to compare the in-hospital mortality of patients with acute decompensated heart failure (ADHF) who were receiving parenteral treatment with one of four intravenous vasoactive medications...
  60. ncbi request reprint Risk stratification for in-hospital mortality in acutely decompensated heart failure: classification and regression tree analysis
    Gregg C Fonarow
    Ahmanson UCLA Cardiomyopathy Center, University of California, Los Angeles Medical Center, Los Angeles, CA 90095, USA
    JAMA 293:572-80. 2005
    ..Estimation of mortality risk in patients hospitalized with acute decompensated heart failure (ADHF) may help clinicians guide care...
  61. ncbi request reprint Influence of blood pressure on the effectiveness of a fixed-dose combination of isosorbide dinitrate and hydralazine in the African-American Heart Failure Trial
    Inder S Anand
    VA Medical Center, Minneapolis, Minnesota, USA
    J Am Coll Cardiol 49:32-9. 2007
    ....
  62. ncbi request reprint Acute heart failure associated with high admission blood pressure--a distinct vascular disorder?
    Olga Milo-Cotter
    Duke University Medical Center and the Duke Clinical Research Institute, Durham NC, 27515, USA
    Eur J Heart Fail 9:178-83. 2007
    ..Although blood pressure (BP) is elevated in patients with acute heart failure (AHF), first admission BP has not been meticulously recorded before treatment in previous studies...
  63. pmc Effects of digoxin on morbidity and mortality in diastolic heart failure: the ancillary digitalis investigation group trial
    Ali Ahmed
    University of Alabama at Birmingham, 1530 3rd Ave S, CH 19, Suite 219, Birmingham AL 35294 2041, USA
    Circulation 114:397-403. 2006
    ..Although digoxin was tested in an appreciable number of diastolic heart failure patients in the Digitalis Investigation Group ancillary trial, detailed findings from this important study have not previously been published...
  64. ncbi request reprint Relation of sex to morbidity and mortality in patients with heart failure and reduced or preserved left ventricular ejection fraction
    Francois Alla
    Department of Epidemiology, University Hospital of Nancy, Nancy, France
    Am Heart J 153:1074-80. 2007
    ..Whether women with chronic heart failure are at less risk for hospitalization for worsening heart failure has not been well investigated...
  65. ncbi request reprint Beta-blocker use and outcomes among hospitalized heart failure patients
    Javed Butler
    Cardiovascular Medicine Division, Vanderbilt University, Nashville, Tennessee, USA
    J Am Coll Cardiol 47:2462-9. 2006
    ....
  66. pmc Digoxin and reduction in mortality and hospitalization in heart failure: a comprehensive post hoc analysis of the DIG trial
    Ali Ahmed
    University of Alabama at Birmingham, VA Medical Center, 1530 3rd Avenue South, CH 19, Ste 219, Birmingham, AL 35294 2041, USA
    Eur Heart J 27:178-86. 2006
    ..To determine the effects of digoxin on all-cause mortality and heart failure (HF) hospitalizations, regardless of ejection fraction, accounting for serum digoxin concentration (SDC)...
  67. ncbi request reprint Improvement in hyponatremia during hospitalization for worsening heart failure is associated with improved outcomes: insights from the Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Chronic Heart Failure (ACTIV in CHF) trial
    Joseph Rossi
    Feinberg School of Medicine Northwestern University, Chicago, Illinois 60611, USA
    Acute Card Care 9:82-6. 2007
    ..Hyponatremia predicts poor outcome in patients with acute heart failure syndromes. This study evaluated the relationship between baseline serum sodium, change in serum sodium, and 60-day mortality in hospitalized heart failure patients...
  68. ncbi request reprint Tezosentan in patients with acute heart failure and acute coronary syndromes: design of the fourth Randomized Intravenous Tezosentan Study (RITZ-4)
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center and Duke Clinical Research Institute, Durham, NC 27705, USA
    Am Heart J 145:S58-9. 2003
  69. doi request reprint Hyponatraemia in acute heart failure is a marker of increased mortality but not when associated with hyperglycaemia
    Olga Milo-Cotter
    Momentum Research, Inc, Durham, NC 27707, USA
    Eur J Heart Fail 10:196-200. 2008
    ..Although diabetes is a common co-morbidity in heart failure, no prior study has considered the impact of serum glucose on this relationship...
  70. ncbi request reprint Anemia as a risk factor and therapeutic target in heart failure
    G Michael Felker
    Duke Clinical Research Institute, Durham, North Carolina 27715, USA
    J Am Coll Cardiol 44:959-66. 2004
    ..Multiple ongoing studies will provide definitive data on the balance of risks and benefits of anemia treatment in chronic HF...
  71. ncbi request reprint Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure
    CHRISTOPHER M O'CONNOR
    Duke University Medical Center, Durham, NC 27705, USA
    Am Heart J 145:S47-50. 2003